ArticleOncoTargets and therapy2017
Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Case Series: EGFR and ROS-1 Co-Occurrence in Advanced Non-Small Cell Lung Cancer.Journal of immunotherapy and precision oncology · 2024Article
- Concomitant epidermal growth factor receptor mutation/c-ros oncogene 1 rearrangement in non-small cell lung cancer: A case report.World journal of clinical oncology · 2024Article
- Correlation analysis between driver gene mutation and clinicopathological features in lung adenocarcinoma based on real-world cumulative clinical data.Translational lung cancer research · 2024Article
- Remarkable response to third-generation EGFR-TKI plus crizotinib in a patient with pulmonary adenocarcinoma harboring EGFR and ROS1 co-mutation: a case report.Frontiers in oncology · 2024Article
- Modern therapies of nonsmall cell lung cancer.Journal of applied genetics · 2023Review
- Personal and clinical characteristics associated with immunotherapy effectiveness in stage IV non-small cell lung cancer.Translational lung cancer research · 2023Article
- Case report: ConcomitantFrontiers in pharmacology · 2023Article
- The potential and limitation of targeted chromosomal breakpoint sequencing for theAmerican journal of cancer research · 2022Article
- Deepening the Knowledge ofInternational journal of molecular sciences · 2021Review
- Testing forOncoTargets and therapy · 2021Review
- A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients.World journal of surgical oncology · 2020Article
- Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes.Journal of cancer research and clinical oncology · 2020Article
- Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review.Frontiers in oncology · 2020Review
- Next Generation Sequencing Reveals a Synchronous Trilateral Lung Adenocarcinoma Case with Distinct Driver Alterations of EGFR 19 Deletion or EGFR 20 Insertion or EZR-ROS1 Fusion.OncoTargets and therapy · 2020Article
- Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: Case series.Medicine · 2019Article
- Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Genomic Profiling on an Unselected Solid Tumor Population Reveals a Highly Mutated Wnt/β-Catenin Pathway Associated with Oncogenic EGFR Mutations.Journal of personalized medicine · 2018Article
- Concurrent EGFR mutation and ALK rearrangement in stage IV lung adenocarcinoma-a case report and a literature review.Porto biomedical journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to explore the frequencies of MATERIALS AND
methodsA total of 421
resultsThe mutations of
conclusionConcomitant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.